Sugi Predict

Sugi Predict / Targets / CXCR5

CXCR5

C-X-C chemokine receptor type 5 · P32302 · CXCR5 on Sugi Atlas →

10,551 patent compounds predicted against CXCR5, 5,705 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1560889 SCHEMBL1560889 0.52 20/20
SCHEMBL1560542 SCHEMBL1560542 0.61 19/20
SCHEMBL1560998 SCHEMBL1560998 0.51 19/20
SCHEMBL1425219 SCHEMBL1425219 0.48 18/20
SCHEMBL1561417 SCHEMBL1561417 0.46 15/20
SCHEMBL1561375 SCHEMBL1561375 0.44 15/20
SCHEMBL1560275 SCHEMBL1560275 0.44 15/20
SCHEMBL1561497 SCHEMBL1561497 0.45 14/20
SCHEMBL1561173 SCHEMBL1561173 0.44 14/20
SCHEMBL1561352 SCHEMBL1561352 0.44 14/20
SCHEMBL1561596 SCHEMBL1561596 0.44 14/20
SCHEMBL1560326 SCHEMBL1560326 0.43 14/20
SCHEMBL1561412 SCHEMBL1561412 0.41 14/20
SCHEMBL1560511 SCHEMBL1560511 0.49 13/20
SCHEMBL1561694 SCHEMBL1561694 0.48 13/20
SCHEMBL1560197 SCHEMBL1560197 0.45 13/20
SCHEMBL1560997 SCHEMBL1560997 0.44 13/20
SCHEMBL1560905 SCHEMBL1560905 0.44 13/20
SCHEMBL1561444 SCHEMBL1561444 0.43 13/20
SCHEMBL1560860 SCHEMBL1560860 0.42 13/20

Clinical trials — most relevant to CXCR5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms PHASE3UNKNOWN
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia PHASE3SUSPENDED
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients PHASE1/PHASE2COMPLETED
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) PHASE1/PHASE2RECRUITING
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma PHASE1/PHASE2COMPLETED
Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis PHASE2COMPLETED
First Time in Human Study With GSK1325756 PHASE1COMPLETED
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study EARLY_PHASE1RECRUITING
Application of 68Ga-Pentixafor PET/CT for Thymoma EARLY_PHASE1UNKNOWN
Comparative Study Between Alzheimer's and Multi-infarct Dementia nanUNKNOWN
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE nanUNKNOWN
ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib nanCOMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA nanRECRUITING
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma nanUNKNOWN
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
The Influence of Extracorporeal Photopheresis on Skin Sclerosis nanCOMPLETED
Diagnostic and Prognostic Biomarkers for IgG4-related Disease. nanUNKNOWN
Measuring the Healthy Pediatric Inflammatory Response to Vaccination. nanENROLLING_BY_INVITATION
Role of Chemokines and Proinflammatory Cytokines in Rheumatoid Synovial Pathological Changes nanWITHDRAWN
Activation and Recruitment of GIL During Hp Infection nanUNKNOWN
The Role of Cxcr4Hi neutrOPhils in InflueNza nanRECRUITING
Involvement of Skeletal Muscle Fibrocytes in sarcOpenia in Patients With Chronic ObstRuctive Pulmonary Disease nanCOMPLETED
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN
Value of Various Chemokines in the Detection and Follow up of RCC nanUNKNOWN
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism. nanNOT_YET_RECRUITING
Preliminary Study of CXCL3 As a Biomarker of Diabetic Kidney Disease nanCOMPLETED
Evaluation of CCR6 Gene Expression and Circulating CCL20 Levels as Potential Biomarkers in Rheumatoid Arthritis nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CXCR5 binder may also engage these)

ProteinNameSimilarity
P34997 — 1.000 P34997 →
Q04683 — 0.996 Q04683 →
E9QJ73 — 0.993 E9QJ73 →
O08707 — 0.988 O08707 →
Q2YEG0 — 0.987 Q2YEG0 →
Q0VDU3 — 0.986 Q0VDU3 →
P35411 — 0.986 P35411 →
Q9N0Z0 — 0.986 Q9N0Z0 →
P56412 — 0.985 P56412 →
Q2YEF9 — 0.985 Q2YEF9 →
Q28003 — 0.985 Q28003 →
O09027 — 0.985 O09027 →
Q2KTE1 — 0.985 Q2KTE1 →
CXCR2 C-X-C chemokine receptor type 2 0.985 landscape →
P70612 — 0.985 P70612 →
P55920 — 0.984 P55920 →
Q0II78 — 0.984 Q0II78 →
Q9BDS8 — 0.984 Q9BDS8 →
O54814 — 0.984 O54814 →
CXCR1 C-X-C chemokine receptor type 1 0.983 landscape →
Q9Z0D9 — 0.983 Q9Z0D9 →
Q9WV08 — 0.983 Q9WV08 →
P43142 — 0.983 P43142 →
Q9TSQ8 — 0.983 Q9TSQ8 →
P35351 — 0.983 P35351 →
Q89609 — 0.983 Q89609 →
Q2Y2P0 — 0.983 Q2Y2P0 →
Q149R9 — 0.983 Q149R9 →
Q2YEG2 — 0.983 Q2YEG2 →
Q1ZY22 — 0.982 Q1ZY22 →